Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Advaxis stock | 0.3951

Own Advaxis stock in just a few minutes.

Posted

Fact checked

Advaxis, Inc is a biotechnology business based in the US. Advaxis shares (ADXS) are listed on the NASDAQ and all prices are listed in US Dollars. Advaxis employs 35 staff and has a trailing 12-month revenue of around USD$254,000.

How to buy shares in Advaxis

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Advaxis. Find the stock by name or ticker symbol: ADXS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Advaxis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.3951, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Advaxis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Advaxis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Advaxis's share price?

Since the stock market crash in March caused by coronavirus, Advaxis's share price has had significant negative movement.

Its last market close was USD$0.3951, which is 59.50% down on its pre-crash value of USD$0.9755 and 6.30% down on the lowest point reached during the March crash when the shares fell as low as USD$0.42.

If you had bought USD$1,000 worth of Advaxis shares at the start of February 2020, those shares would have been worth USD$598.94 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$464.01.

Advaxis share price

Use our graph to track the performance of ADXS stocks over time.

Advaxis shares at a glance

Information last updated 2020-10-20.
Latest market close USD$0.3951
52-week range USD$0.2625 - USD$1.48
50-day moving average USD$0.4199
200-day moving average USD$0.573
Wall St. target price USD$5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.094

Buy Advaxis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Advaxis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Advaxis price performance over time

Historical closes compared with the close of $0.3951 from 2020-11-16

1 week (2020-11-20) 2.76%
1 month (2020-10-27) 0.28%
3 months (2020-08-27) -17.34%
6 months (2020-05-27) -44.35%
1 year (2019-11-27) -9.17%
2 years (2018-11-27) -7.49%
3 years (2017-11-27) -87.09%
5 years (2015-11-27) -96.75%

Advaxis financials

Revenue TTM USD$254,000
Gross profit TTM USD$20.9 million
Return on assets TTM -36.43%
Return on equity TTM -74.81%
Profit margin 0%
Book value $0.502
Market capitalisation USD$30.5 million

TTM: trailing 12 months

Shorting Advaxis shares

There are currently 1.4 million Advaxis shares held short by investors – that's known as Advaxis's "short interest". This figure is 9.1% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Advaxis shares can be evaluated.

Advaxis's "short interest ratio" (SIR)

Advaxis's "short interest ratio" (SIR) is the quantity of Advaxis shares currently shorted divided by the average quantity of Advaxis shares traded daily (recently around 1.7 million). Advaxis's SIR currently stands at 0.82. In other words for every 100,000 Advaxis shares traded daily on the market, roughly 820 shares are currently held short.

However Advaxis's short interest can also be evaluated against the total number of Advaxis shares, or, against the total number of tradable Advaxis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Advaxis's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Advaxis shares in existence, roughly 20 shares are currently held short) or 0.0214% of the tradable shares (for every 100,000 tradable Advaxis shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Advaxis.

Find out more about how you can short Advaxis stock.

Advaxis share dividends

We're not expecting Advaxis to pay a dividend over the next 12 months.

Have Advaxis's shares ever split?

Advaxis's shares were split on a 1:15 basis on 29 March 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Advaxis shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Advaxis shares which in turn could have impacted Advaxis's share price.

Advaxis share price volatility

Over the last 12 months, Advaxis's shares have ranged in value from as little as $0.2625 up to $1.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Advaxis's is 3.4021. This would suggest that Advaxis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Advaxis overview

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site